+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Multi Cancer Early Detection Market and Forecasts 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • July 2025
  • Region: Global
  • DPI Research
  • ID: 6111090

Multi Cancer Early Detection Market Poised for Expansion with Liquid Biopsy and Gene Panel Innovations Leading the Way

The global multi cancer early detection market size was valued at USD 1 billion in 2024 and is likely to reach USD 4.3 billion by 2033, expanding at a CAGR 16.9% during the forecast period.

The multi cancer early detection market is experiencing significant growth as advancements in technology and changing healthcare paradigms evolve. Early detection of cancer can lead to improved treatment outcomes and potentially save lives, making this market increasingly important in the realm of healthcare.

One of the primary drivers of the multi cancer early detection market is the rapid advancement of diagnostic technologies. Innovations in genomics, artificial intelligence, and imaging techniques are enhancing the accuracy and efficiency of cancer detection. These cutting-edge technologies allow for the identification of multiple cancer types simultaneously, which is crucial for timely intervention.

Another key factor contributing to the market’s expansion is the growing public awareness regarding the importance of early cancer detection. More individuals are prioritizing preventive healthcare measures, leading to increased screenings and tests. Health campaigns and education initiatives are empowering patients to take charge of their health, thereby stimulating demand for multi-cancer early detection solutions.

Multi Cancer Early Detection Market Synopsis

This new 2025 market report presents an in-depth assessment of the global multi cancer early detection market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global multi-cancer early detection market. The report also provides up-to-date historical market size data for the period 2020 - 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global multi cancer early detection market.

The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global multi cancer early detection market segments, and a vivid forecast to 2033.

It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and regions. The report also offers analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report also provides a detailed description of the porter’s five forces analysis, PESTEL analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global multi cancer early detection market.

The report concludes with the profiles of major market players in the global multi cancer early detection market. The key market players are evaluated on various parameters such as company overview, product landscape, recent developments in multi cancer early detection, funding & M&A, strategic outlook, challenges and risks of the global multi cancer early detection market.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global multi cancer early detection market are determined with utmost precision.

Multi Cancer Early Detection Market Segmentation

The global market for multi cancer early detection is split based on types, end user, and geography.

Multi Cancer Early Detection Market by Types

  • Gene Panel, IDT & Others
  • Liquid Biopsy

Multi Cancer Early Detection Market by End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

Multi Cancer Early Detection Market by Regional Outlook

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Multi Cancer Early Detection Market by Country

  • United States
  • Canada
  • Mexico
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Australia
  • China
  • Japan
  • India
  • South Korea
  • Thailand
  • Brazil
  • Argentina
  • Saudi Arabia
  • Kuwait
  • South Africa
  • Rest of World (RoW)

Multi Cancer Early Detection Market by Key Players

  • GRAIL, Inc. (an Illumina Company)
  • Guardant Health
  • Exact Sciences Corporation
  • Illumina, Inc.
  • Freenome Holdings, Inc.
  • Burning Rock Biotech Limited
  • Foundation Medicine, Inc.
  • AnchorDx
  • Beijing Lyman Juntai International Medical Technology Development Co.
  • Genecast
  • Singlera Genomics Inc
  • Thrive Earlier Detection (acquired by Exact Sciences Corporation)

Key Features of the Report

  • The global multi cancer early detection market provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2033).
  • Annualized revenues and country level analysis for each market segment.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Detailed analysis of geographical landscape with country level analysis of major regions.
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter’s five force analysis and PESTEL analysis
  • Through study of the key business strategies and recommendations on future market approach.
  • Comprehensive analysis of the competitive structure of the market.
  • Demand side and supply side analysis of the market.

Key Questions the Report Addresses

  • How big is the global multi cancer early detection market?
  • What is the current multi cancer early detection market size?
  • What is the major driving factor for the multi cancer early detection market?
  • Which factor is restraining the growth of the multi cancer early detection market?
  • Who are the key players in the multi cancer early detection market?
  • Which region has the biggest share in the multi cancer early detection market?
  • Which is the fastest growing country in the multi cancer early detection market?

Table of Contents


1. Market Definition2. Research and Methodology3. Executive Summary
4. Global Multi Cancer Early Detection - Market Dynamics
4.1 Growth Drivers
4.2 Challengers
4.3 Funding and Merger & Acquisitions

5. Global Multi Cancer Early Detection Market - Industry Analysis
5.1 SWOT Analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2 Porter’s Analysis
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Bargaining Power of Buyers
5.2.4 Threat of Substitute Products or Services
5.2.5 Rivalry Among Existing Competitors

6. Global Multi Cancer Early Detection (MCED) Market & Forecast (2020-2033)
7. Global Multi Cancer Early Detection (MCED) Market Share & Forecast (2020-2033)
7.1 By Types
7.2 By End Use
7.3 By Region
7.4 By Country

8. By Types - Global Multi Cancer Early Detection (MCED) Market & Forecast (2020-2033)
8.1 Gene Panel, IDT & Others
8.2 Liquid Biopsy

9. By End Use - Global Multi Cancer Early Detection (MCED) Market & Forecast (2020-2033)
9.1 Hospitals
9.2 Diagnostic Laboratories
9.3 Others

10. By Region - Global Multi Cancer Early Detection (MCED) Market & Forecast (2020-2033)
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa

11. By Country - Global Multi Cancer Early Detection (MCED) Market & Forecast (2020-2033)
11.1 United States
11.1.1 Market Size
11.1.2 Growth Drivers
11.1.3 Country Pricing Landscape
11.1.4 Regulatory Policy & Reimbursements
11.2 Canada
11.2.1 Market Size
11.2.2 Growth Drivers
11.2.3 Country Pricing Landscape
11.2.4 Regulatory Policy & Reimbursements
11.3 Mexico
11.3.1 Market Size
11.3.2 Growth Drivers
11.3.3 Country Pricing Landscape
11.3.4 Regulatory Policy & Reimbursements
11.4 United Kingdom
11.4.1 Market Size
11.4.2 Growth Drivers
11.4.3 Country Pricing Landscape
11.4.4 Regulatory Policy & Reimbursements
11.5 Germany
11.5.1 Market Size
11.5.2 Growth Drivers
11.5.3 Country Pricing Landscape
11.5.4 Regulatory Policy & Reimbursements
11.6 France
11.6.1 Market Size
11.6.2 Growth Drivers
11.6.3 Country Pricing Landscape
11.6.4 Regulatory Policy & Reimbursements
11.7 Italy
11.7.1 Market Size
11.7.2 Growth Drivers
11.7.3 Country Pricing Landscape
11.7.4 Regulatory Policy & Reimbursements
11.8 Spain
11.8.1 Market Size
11.8.2 Growth Drivers
11.8.3 Country Pricing Landscape
11.8.4 Regulatory Policy & Reimbursements
11.9 Denmark
11.9.1 Market Size
11.9.2 Growth Drivers
11.9.3 Country Pricing Landscape
11.9.4 Regulatory Policy & Reimbursements
11.10 Australia
11.10.1 Market Size
11.10.2 Growth Drivers
11.10.3 Country Pricing Landscape
11.10.4 Regulatory Policy & Reimbursements
11.11 China
11.11.1 Market Size
11.11.2 Growth Drivers
11.11.3 Country Pricing Landscape
11.11.4 Regulatory Policy & Reimbursements
11.12 India
11.12.1 Market Size
11.12.2 Growth Drivers
11.12.3 Country Pricing Landscape
11.12.4 Regulatory Policy & Reimbursements
11.13 Japan
11.13.1 Market Size
11.13.2 Growth Drivers
11.13.3 Country Pricing Landscape
11.13.4 Regulatory Policy & Reimbursements
11.14 South Korea
11.14.1 Market Size
11.14.2 Growth Drivers
11.14.3 Country Pricing Landscape
11.14.4 Regulatory Policy & Reimbursements
11.15 Thailand
11.15.1 Market Size
11.15.2 Growth Drivers
11.15.3 Country Pricing Landscape
11.15.4 Regulatory Policy & Reimbursements
11.16 Brazil
11.16.1 Market Size
11.16.2 Growth Drivers
11.16.3 Country Pricing Landscape
11.16.4 Regulatory Policy & Reimbursements
11.17 Argentina
11.17.1 Market Size
11.17.2 Growth Drivers
11.17.3 Country Pricing Landscape
11.17.4 Regulatory Policy & Reimbursements
11.18 Saudi Arabia
11.18.1 Market Size
11.18.2 Growth Drivers
11.18.3 Country Pricing Landscape
11.18.4 Regulatory Policy & Reimbursements
11.19 Kuwait
11.19.1 Market Size
11.19.2 Growth Drivers
11.19.3 Country Pricing Landscape
11.19.4 Regulatory Policy & Reimbursements
11.20 South Africa
11.20.1 Market Size
11.20.2 Growth Drivers
11.20.3 Country Pricing Landscape
11.20.4 Regulatory Policy & Reimbursements

12. Global Multi Cancer Early Detection Market - Key Players Profiles
12.1 GRAIL, Inc. (an Illumina Company)
12.1.1 Business Overview
12.1.2 MCED Product Landscape
12.1.3 MCED (Galleri) Test Volume
12.1.4 MCED (Galleri) Per Test Average Cost
12.1.5 MCED (Galleri) Test Revenue
12.1.6 SWOT Analysis
12.1.7 Recent Developments in MCED
12.1.8 Funding & M&A
12.1.9 Grail Inc Strategic
12.2 Guardant Health
12.2.1 Business Overview
12.2.2 MCED Product Landscape
12.2.3 MCED (Shield) Test Volume
12.2.4 MCED (Shield) Per Test Average Cost
12.2.5 MCED (Shield) Test Revenue
12.2.6 SWOT Analysis
12.2.7 Recent Developments in MCED
12.2.8 Funding & M&A
12.2.9 Guardant Health Strategic
12.3 Exact Sciences Corporation
12.3.1 Business Overview
12.3.2 MCED Product Landscape
12.3.3 SWOT Analysis
12.3.4 Recent Developments in MCED
12.3.5 Funding & M&A
12.3.6 Exact Sciences Corporation Strategic
12.4 Illumina, Inc.
12.4.1 Business Overview
12.4.2 MCED Product Landscape
12.4.3 SWOT Analysis
12.4.4 Recent Developments in MCED
12.4.5 Funding & M&A
12.4.6 Illumina Inc Strategic
12.5 Freenome Holdings, Inc.
12.5.1 Business Overview
12.5.2 MCED Product Landscape
12.5.3 SWOT Analysis
12.5.4 Recent Developments in MCED
12.5.5 Funding & M&A
12.5.6 Freenome Holdings Strategic
12.6 Burning Rock Biotech Limited
12.6.1 Business Overview
12.6.2 MCED Product Landscape
12.6.3 SWOT Analysis
12.6.4 Recent Developments in MCED
12.6.5 Funding & M&A
12.6.6 Burning Rock Biotech Strategic
12.7 FOUNDATION MEDICINE, INC
12.7.1 Business Overview
12.7.2 MCED Product Landscape
12.7.3 SWOT Analysis
12.7.4 Recent Developments in MCED
12.7.5 Funding & M&A
12.7.6 FOUNDATION MEDICINE Strategic
12.8 AnchorDx
12.8.1 Business Overview
12.8.2 MCED Product Landscape
12.8.3 SWOT Analysis
12.8.4 Recent Developments in MCED
12.8.5 Funding & M&A
12.8.6 AnchorDx Strategic
12.9 Beijing Lyman Juntai International Medical Technology Development Co.
12.9.1 Business Overview
12.9.2 MCED Product Landscape
12.9.3 SWOT Analysis
12.9.4 Recent Developments in MCED
12.9.5 Funding & M&A
12.9.6 Beijing Lyman Juntai International Medical Technology Development Strategic
12.10 GENECAST
12.10.1 Business Overview
12.10.2 MCED Product Landscape
12.10.3 SWOT Analysis
12.10.4 Recent Developments in MCED
12.10.5 Funding & M&A
12.10.6 GENECAST Strategic
12.11 Singlera Genomics Inc.
12.11.1 Business Overview
12.11.2 MCED Product Landscape
12.11.3 SWOT Analysis
12.11.4 Recent Developments in MCED
12.11.5 Funding & M&A
12.11.6 Singlera Genomics Strategic
12.12 Thrive Earlier Detection (acquired by Exact Sciences Corporation)
12.12.1 Business Overview
12.12.2 MCED Product Landscape
12.12.3 SWOT Analysis
12.12.4 Recent Developments in MCED
12.12.5 Funding & M&A
12.12.6 Thrive Earlier Detection Strategic

Companies Mentioned

  • GRAIL, Inc. (an Illumina Company)
  • Guardant Health
  • Exact Sciences Corporation
  • Illumina, Inc.
  • Freenome Holdings, Inc.
  • Burning Rock Biotech Limited
  • FOUNDATION MEDICINE, INC.
  • AnchorDx
  • Beijing Lyman Juntai International Medical Technology Development Co.
  • GENECAST
  • Singlera Genomics Inc.
  • Thrive Earlier Detection (acquired by Exact Sciences Corporation)

Table Information